[ad_1]
Regarding the results of vaccine research, a very strong line must be drawn between the Western world and China and Russia; Unfortunately, political tensions have also closed the gap in scientific cooperation. It is difficult to verify the safety and efficacy of Chinese and Russian vaccines through the usual research validation process in the Western world: peer-reviewed and peer-reviewed scientific articles. Because that data just doesn’t exist yet. But vaccines developed in these countries have a limited distribution even without waiting for the results of phase 3 studies. According to The New York Times, up to 6 different vaccines! 4 Chinese and 2 Russians.
Meanwhile, it is customary in the western world to follow stricter requirements, follow rules, and not take shortcuts. Pfizer and BioNTech have published very promising initial vaccine efficacy data exceeding 90 percent, but that alone is far from allowing the vaccine to be released immediately outside of clinical trials – those trials will need to be completed and calculated. and publish, and national authorities deciding which drugs to register must evaluate all these data and make a decision.
The same process awaits several more “western” test vaccines. And the first results of some of them should also appear in the next few days.
Here Moderna, which is developing a vaccine using similar mRNA technology, as well as teams from Pfizer and BioNTech, has announced that the information is being prepared for submission to an independent data safety monitoring board, which will evaluate the data and will make a recommendation. Dr. Anthony Fauci, director of the US Institute for Communicable Diseases and Allergies, said Wednesday that the data should be released “between a few days and a little later than a week later.” The doctor expects the vaccine to be as effective as 90 percent, similar to Pfizer’s.
The British publication The Telegraph, citing John Bell, a professor at the University of Oxford, said that the first data from clinical trials of the vaccine, which the university was developing with AztraZeneca, could be made public in the coming weeks. Bloomberg wrote in an interview with the director of AstraZeneca that the vaccine could be ready for mass vaccination in humans later this year. There have been several obstacles to testing this vaccine: One patient was diagnosed with a neurological disease after vaccination – transverse myelitis. Another young participant in this study in Brazil died of COVID-19. The vaccine developers did not officially comment on the recent incident, but experts believe that the deceased patient was not in the study but in the control group. After all incidents, clinical trials were suspended and a case-by-case review was performed, after which the decision was made to reopen the trial both times.
Speaking to the Economic Club of Detroit (USA) on Wednesday, the director of Johnson & Johnson was very satisfied with the success of the vaccine being developed by Pfizer and said that this is not a case of companies competing for a best result: it is a global competition to beat COVID. 19, it is not a race to see who will develop the vaccine sooner or who will be better. Unfortunately, no details were provided during this interview about the vaccine status of the Johnson & Johnson study itself and the expected timing of the release of the study data. October 12 The company’s vaccine clinical trials also experienced a serious adverse reaction and the trials were suspended, but after an 11-day hiatus, they were resumed and at that time it was announced that the results were still to be published by the end of this year.
The American company Novavax also expects to present the results of its clinical trials later this year.
Indian company Bharat Biotech is also conducting phase III clinical trials of the COVID-19 vaccine, but these trials only started on October 23, so results are unlikely to be expected this year.
[ad_2]
